Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation
Open accessAbstract
Background: Despite its potential utility in delivering direct tumor killing and in situ whole-cell tumor vaccination, tumor cryoablation produces highly variable and unpredictable clinical response, limiting its clinical utility. The mechanism(s) driving cryoablation-induced local antitumor immunity and the associated abscopal effect is not well understood. Methods: The aim of this study was to identify and explore a mechanism of action by which cryoablation enhances the therapeutic efficacy in metastatic tumor models. We used the subcutaneous mouse model of the rhabdomyosarcoma (RMS) cell lines RMS 76-9 STINGwt or RMS 76-9 STING-/-, along with other murine tumor models, in C57BL/6 or STING-/- (TMEM173-/- ) mice to evaluate local tumor changes, lung metastasis, abscopal effect on distant tumors, and immune cell dynamics in the tumor microenvironment (TME). Results: The results show that cryoablation efficacy is dependent on both adaptive immunity and the STING signaling pathway. Contrary to current literature dictating an essential role of host-derived STING activation as a driver of antitumor immunity in vivo, we show that local tumor control, lung metastasis, and the abscopal effect on distant tumor are all critically dependent on a functioning tumor cell-intrinsic STING signaling pathway, which induces inflammatory chemokine and cytokine responses in the cryoablated TME. This reliance extends beyond cryoablation to include intratumoral STING agonist therapy. Additionally, surveys of gene expression databases and tissue microarrays of clinical tumor samples revealed a wide spectrum of expressions among STING-related signaling components. Conclusions: Tumor cell-intrinsic STING pathway is a critical component underlying the effectiveness of cryoablation and suggests that expression of STING-related signaling components may serve as a potential therapy response biomarker. Our data also highlight an urgent need to further characterize tumor cell-intrinsic STING pathways and the associated downstream inflammatory response evoked by cryoablation and other STING-dependent therapy approaches.
AI snapshot
Written from the paper’s full text.
TL;DR
Cryoablation efficacy in murine sarcoma and pancreatic tumor models depends on adaptive immunity and, unexpectedly, on functional STING signaling within the live residual tumor cells rather than host STING. Tumor cell-intrinsic STING also drives systemic abscopal responses and contributes to intratumoral STING agonist therapy, with clinical sarcoma data showing variable STING pathway expression.
Key findings
- Cryoablation required adaptive immunity: in nude mice the effect was greatly reduced and all mice succumbed after the last measurement on day 21; CD4+ T-cell depletion partially abrogated regression, while CD8+ T-cell depletion resulted in tumor growth not significantly different from untreated tumors.
- Tumor cell-intrinsic STING was critical: cryoablation of RMS 76-9STING−/− tumors was completely ineffective in C57BL/6 mice despite intact host STING, with significantly increased lung metastases; in STING−/− mice, cryoablation of RMS 76-9STINGwt still significantly inhibited tumor growth and lung metastases, whereas STING−/− tumors did not benefit. Similar results were seen with M3-9-M and KPC1242 models.
- The abscopal effect depended on the primary tumor’s STING: cryoablation of RMS 76-9STINGwt primary tumors significantly reduced untreated contralateral RMS 76-9STINGwt secondary tumors in both C57BL/6 and STING−/− mice, but this effect was lost when the primary tumor was STING−/−.
- Intratumoral DMXAA (250 µg) efficacy was also tumor-intrinsic STING-dependent: absence of STING in tumor cells or host alone partially suppressed tumor growth, while absence in both completely abolished in vivo antitumor efficacy. Clinical surveys found wide variation in STING pathway components across 2142 PeCan samples and an RMS tissue microarray from 104 patients, with lower Tmem173 and Tbk1 transcript expression in metastatic/relapsed RMS versus primary tumors.
Methods
- Subcutaneous mouse tumor models used RMS 76-9STINGwt or CRISPR-generated RMS 76-9STING−/− cells, plus M3-9-M and KPC1242 counterparts, in male C57BL/6, nude, or STING−/− mice; only male mice were used because RMS 76-9 originated from male mice and female mice reject H-Y-dependent tumors.
- Primary tumors were cryoablated at ~100 mm³ with three cycles of 1 min freeze and 3 min thaw; outcomes included local tumor growth, lung metastasis, dual-tumor abscopal effect, TME immune profiling by flow cytometry/t-SNE, qPCR, ELISA, chemokine/cytokine arrays, western blot, immunohistochemistry, and confocal imaging.
- In vitro assays included BMDC and BMDM co-culture with cryoablated tumor cells, DMXAA treatment, proliferation/cell death analysis, and STING pathway validation; statistics used GraphPad Prism V8 with mean ± SEM, two-tailed t-tests, one-way or two-way ANOVA with Bonferroni’s multiple comparisons.
Limitations
- Stated: the study used a single cryoablation intervention to standardize parameters, so whether different timing, duration, or frequency would enhance antitumor immunity remains undetermined; the abscopal tumors remained sizeable and many progressed, suggesting combination therapy such as immune checkpoint blockade may be needed; whether the effect converges on IFN-β, chemokines, or other undiscovered effectors remains to be determined; direct effects of tumor-intrinsic STING on metastatic potential versus immunogenicity require further investigation.
- Evident from the text: only male mice were used, limiting sex-related generalizability; the clinical STING expression analyses are correlative surveys of databases and tissue microarrays rather than causal clinical validation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
32 of 48 cited sources checked · 9 supported · 0 flagged · accuracy not yet measured
- Premisecitation
CD8+IFN-γ+ T cells are an effector population shown to be a target of downstream STING signaling involving the IFN-β-CXCL9/10 axis.
“an effector population shown to be a target of downstream STING signaling involving the IFN-β-CXCL9/10 axis.54–58”
Quote in the paperSubstantial claim5 of 5 sources checked- cites [54] source
The sections “Regulation of the STING pathway in APCs and its role in cancer” and “Type I IFNs in the generation of antitumor immune responses” link STING activation to IFN-β production and antitumor CD8+ T-cell responses. The latter section also associates CXCL9 and CXCL10 with T-cell recruitment, but our copy does not establish the stated IFN-β–CXCL9/10 signaling axis or identify CD8+IFN-γ+ T cells specifically as its target. (LLM, conf=0.85)
Experimental — accuracy not yet measured - cites [55] source
The Results section (page unavailable) shows that CXCL9 and CXCL10 recruit human CD8+ effector T cells in migration assays. It does not identify those cells as IFN-γ+ or establish that their recruitment is downstream of STING signaling through IFN-β. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [56] Vonderhaar, 2021, STING activated tumor-intrinsic type I interferon signaling promotes Cxcr3 dependent antitumor immunity in Pancreatic cancer, Cell Mol Gastroenterol Hepatol source
The Results section reports that STING agonist increased IFN-β expression and the frequency of CXCR3+CD8+ T cells in pancreatic tumor models. The Discussion links STING activation, type I interferon signaling, and CXCL9/CXCL10 to effector T-cell infiltration. Our copy does not establish that the affected CD8+ cells were specifically IFN-γ+. (LLM, conf=0.85)
Experimental — accuracy not yet measured - cites [57] source
The Results section reports reduced T-cell infiltration in STING-deficient tumors and links effector T-cell migration to CXCL9/10-producing dendritic cells; it also describes STING-dependent IFN-β and CXCL9/10 production. The paper supports this pathway for effector CD8+ T-cell recruitment, but does not establish that the recruited CD8+ cells are specifically IFN-γ-positive. Its Discussion separately identifies IFN-γ-producing CD4+ Th1 cells. (LLM, conf=0.85)
Experimental — accuracy not yet measured - cites [58] Reschke R , Olson DJ . Leveraging STING, Batf3 Dendritic cells, Cxcr3 ligands, and other components related to innate immunity to induce A "hot. Cancers (Basel 2022;14(10. source
Section 3.1 (page unavailable) states that STING-induced CXCL9/10 expression depends on type I interferons, including IFN-β. Section 3 (page unavailable) says CXCL9/10 promote T-cell migration and are associated with CD8+ effector T cells. The paper does not specifically identify CD8+IFN-γ+ T cells as a demonstrated target of that signaling axis. (LLM, conf=0.85)
Experimental — accuracy not yet measured
- Premisecitation
Clinical outcomes of tumor cryoablation-both obtaining local control and achieving an abscopal effect-are highly unpredictable with variable magnitudes of response and frequent failure of local recurrence.
“Despite these theoretical benefits, clinical outcomes of tumor cryoablation—both obtaining local control and achieving an abscopal effects—are highly unpredictable with variable magnitudes of response and frequent failure of local recurrence.”
Quote in the paperSubstantial claim3 of 3 sources checked- cites [76] Aarts, 2019, Cryoablation and Immunotherapy: an overview of evidence on its synergy, Insights Imaging source
The Abstract and Introduction say the abscopal effect is rarely observed, supporting that part of the claim. But the Conclusion says cryoablation has proven successful for local control in various cancers; it does not describe local control as highly unpredictable or report frequent local failure. The cited passages also do not establish variable magnitudes of clinical response. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [77] Yakkala, 2019, Cryoablation and Immunotherapy: an enthralling synergy to confront the tumors, Front Immunol source
The ‘Critical Aspects’ section (page unavailable) says some patients experience local tumor progression after cryoablation and that factors governing its effects remain ill-defined. The ‘Immunology of Cryoablation’ section (page unavailable) describes variable immune responses and limited abscopal regression. These passages support uncertainty in outcomes, but the source says only a fraction of patients have local progression, not that local failure is frequent. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites [78] Baust, 2019, Cryoablation: physical and molecular basis with putative immunological consequences, Int J Hyperthermia source
The Cryo-immunological Responses section (page unavailable) says distant-tumor effects are not always observed, are transient, and vary in extent; the Introduction says freezing does not damage a targeted tumor uniformly. These passages support variable responses, but they do not establish that clinical local control is highly unpredictable or that local recurrence frequently occurs. (LLM, conf=0.84)
Experimental — accuracy not yet measured
- Premisecitation
Gain-of-function STING-N153S mutation resulted in T cell deficiency.
“and gain-of-function STING-N153S mutation resulted in T cell deficiency.85”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [85] source
- Premisecitation
STING activity induces T cell apoptosis.
“as recent evidence demonstrated that STING activity induces T cell apoptosis,85–87”
Quote in the paperSubstantial claim3 of 3 sources checked- cites [85] source
- cites [86] Gulen, 2017, Signalling strength determines Proapoptotic functions of STING, Nat Commun source
- cites [87] source
The Results and Discussion section (“STING activation triggers T cell death”; page not provided) reports STING-dependent T-cell death in vitro and evidence implicating an apoptotic pathway. But it also suggests necroptosis can contribute and reports no T-cell death in its short-term in vivo experiment, so the unqualified claim that STING activity induces T-cell apoptosis overstates the finding. (LLM, conf=0.87)
Experimental — accuracy not yet measured
- Findingown data
Cryoablation of RMS 76-9STING-/- tumors in C57BL/6 mice was rendered completely ineffective, despite functionally intact STING signaling in the host.
“cryoablation of RMS 76-9STING-/- tumors in C57BL/6 mice was rendered completely ineffective, despite the presence of functionally intact STING signaling in the host (figure 4A).”
Quote in the paperSubstantial claim
- Findingown data
Removal of CD8+ T cells resulted in tumor growth that was not significantly different from untreated tumors.
“removal of CD8+ T cells resulted in tumor growth that was not significantly different from untreated tumors (figure 1D, online supplemental figure S1).”
Quote in the paperSubstantial claim - Findingown data
RMS 76-9STING-/- cells exhibit faster growth kinetics in vitro compared with RMS 76-9STINGwt cells.
“Although RMS 76-9STING-/- exhibit faster growth kinetics in vitro as compared with RMS 76-9STINGwt (online supplemental figure S8A)”
- Also stated in: § Tumor-intrinsic STING mediates antitumor immune responses following cryoablation · plain
“at baseline we saw a growth advantage of RMS 76-9STING-/- tumor as compared with RMS 76-9STINGwt tumor (online supplemental figure S8A) in vitro.”
Quote in the paperNot a substantial claim - Also stated in: § Tumor-intrinsic STING mediates antitumor immune responses following cryoablation · plain
- Findingown data
A higher percent of MHC II and CD80 expressing DCs were found in cryoablated TME compared with non-cryoablated group.
“A higher percent of MHC II and CD80 expressing DCs were found in cryoablated TME as compared with those in the non-cryoablated group (figure 2B).”
Quote in the paperSubstantial claim - Findingown data
On exposure to dead tumor lysate, Ifn-β transcription was upregulated only in live RMS 76-9STINGwt cells, while live RMS 76-9STING-/- cells remained unaffected.
“On exposure to dead tumor lysate, Ifn-β transcription was upregulated only in the live RMS 76-9STINGwt, while live RMS 76-9STING-/- cells remained unaffected (online supplemental figure S4E).”
Quote in the paperSubstantial claim - Findingown data
Total IFN-β increased in both RMS 76-9STINGwt and M3-9-MSTINGwt TME compared with STING-/- tumor TME following cryoablation.
“Total IFN-β increased in both RMS 76-9STINGwt (figure 3F) and M3-9-MSTINGwt TME (figure 7A) as compared with the STING-/- tumor TME following cryoablation.”
Quote in the paperSubstantial claim - Findingown data
A significant increase in RMS lung metastases was observed in C57BL/6 mice with cryoablated RMS 76-9STING-/- tumors.
“we also observed a significant increase in RMS lung metastases in the same group (figure 4B,C)”
Quote in the paperSubstantial claim - Findingown data
Cryoablation of RMS 76-9 tumors significantly increases IFN-β production in the TME 3 days after cryoablation compared with non-ablated TME.
“we assessed and observed a significant increase in the amount of IFN-β production in the TME 3 days after cryoablation as compared with non-ablated TME (figure 3A).”
Quote in the paperSubstantial claim - Findingown data
Both RMS 76-9STINGwt and RMS 76-9STING-/- cell lines exhibit similar tumor growth kinetics in C57BL/6 mice in the absence of cryoablation.
“both cell lines exhibit similar tumor growth kinetics in C57BL/6 mice in the absence of cryoablation (figure 4A).”
Quote in the paperSubstantial claim - Findingown data
Two additional RMS 76-9STING-/- tumor clones, Clones 7 and 8, either alone or in combination, showed the same phenomenon of complete loss of antitumor efficacy following cryoablation as seen in figure 4A.
“we tested two additional RMS 76-9STING-/- tumor clones, Clones 7 and 8, either alone or in combination, and observed the same phenomenon of a complete loss of antitumor efficacy following cryoablation as seen in figure 4A, online supplemental figure S5).”
Quote in the paperSubstantial claim - Findingown data
Cryotherapy increases Il-12β transcription in DCs isolated from cryoablated TME in vivo.
“Similarly, cryotherapy of RMS 76-9 increases Il-12β transcription by co-cultured BMDCs in vitro (figure 2C) as well as in DCs isolated from cryoablated TME in vivo (figure 2D).”
Quote in the paperSubstantial claim - Findingown data
In DMXAA-treated RMS 76-9STING-/- cells, upregulation of IFN-β and phosphorylation of IRF3 were decreased compared with wild-type cells.
“Both the upregulation of IFN-β (online supplemental figure S4C) and the phosphorylation of IRF3 (online supplemental figure S4D) were decreased in DMXAA-treated RMS 76-9STING-/- as compared with wild-type cells.”
Quote in the paperSubstantial claim - Findingown data
Cryoablation of STINGwt tumor dramatically increases a variety of chemokines and cytokines, including CXCL9 and CXCL10.
“Cryoablation of STINGwt tumor dramatically increases a variety of chemokines and cytokines, including the canonical chemokines, CXCL9 and CXCL10, as well as a variety of others (figure 7B–D).”
Quote in the paperSubstantial claim - Findingown data
Cryoablated tumor TME harbored a significant increase in the frequency of CD45+ cells.
“Cryoablated tumor TME harbored a significant increase in the frequency of CD45+ cells (figure 2F).”
Quote in the paperSubstantial claim - Findingown data
In contrast to wild-type mice, the significant changes in frequency of CD4+ T cells expressing IFN-γ or GZMB, and the frequency and intensity of GZMB-expressing CD8+ T cells were lost in STING-/- mice.
“In contrast to wild-type mice, the significant changes in frequency of CD4+ T cells expressing IFN-γ (figure 5G) or GZMB (figure 5I), and the frequency and intensity of GZMB-expressing CD8+ T cells (figure 5J,K) were lost.”
Quote in the paperSubstantial claim- Rests on an assumption: STING-/- mice lack functional host STING signaling.
- Findingown data
No significant changes were observed in the myeloid cell populations within the cryoablated TME of either tumors.
“We did not observe any significant changes in the myeloid cell populations within the cryoablated TME of either tumors (figure 4O,P).”
Quote in the paperNot a substantial claim - Findingown data
Cryoablation of RMS 76-9STINGwt tumor in wild-type mice induced sustained local tumor control.
“cryoablation of RMS 76-9STINGwt tumor in wild-type mice not only induced sustained local tumor control (figure 4A)”
Quote in the paperSubstantial claim - Findingown data
Cryoablated RMS decreased BMDM expression of CD206+ under similar co-culture conditions.
“cryoablated RMS also decreased bone marrow-derived macrophage (BMDM) expression of CD206+ under similar co-culture conditions (figure 2E).”
Quote in the paperNot a substantial claim - Findingown data
Cryotherapy of RMS 76-9 increases Il-12β transcription by co-cultured BMDCs in vitro.
“cryotherapy of RMS 76-9 increases Il-12β transcription by co-cultured BMDCs in vitro (figure 2C)”
Quote in the paperSubstantial claim - Findingown data
Conventional flow cytometry confirmed a significant increase in IFN-γ-expressing CD45+/CD3+/CD8+ TILs and CD3+ TILs post cryoablation of RMS 76-9STINGwt tumor compared with RMS 76-9STING-/- tumor in STING-/- mice.
“Conventional flow cytometry analysis confirmed a significant increase in IFN-γ-expressing CD45+/CD3+/CD8+ TILs (figure 5E, F and H), and CD3+ TILs post cryoablation of RMS 76-9STINGwt tumor as compared with RMS 76-9STING-/- tumor in the setting of STING-/- mice”
Quote in the paperSubstantial claim- Rests on an assumption: STING-/- mice lack functional host STING signaling.
- Findingown data
Depletion of CD4+ T cells resulted in partial abrogation of cryoablation-induced tumor regression.
“depletion of CD4+ T cells resulted in partial abrogation of the observed cryoablation-induced tumor regression (figure 1C, online supplemental figure S1)”
Quote in the paperSubstantial claim - Findingown data
IFN-β production in the TME of tumor-bearing STING-/- mice was similarly enhanced 3 days following cryoablation as in wild-type mice.
“IFN-β production in the TME of tumor-bearing STING-/- mice were similarly enhanced 3 days following cryoablation as in wild-type mice (figure 3A, online supplemental figure S4F).”
Quote in the paperSubstantial claim- Rests on an assumption: STING-/- mice lack functional host STING signaling.
- Findingown data
Cryoablation of established RMS tumor in STING-/- mice resulted in a significant partial reduction in tumor size over the subsequent 2 weeks, although not as robust as in wild-type mice.
“cryoablation of established RMS tumor in STING-/- mice resulted in a significant partial reduction in tumor size over the subsequent 2 weeks, although there was not as robust of a response as seen in wild-type mice (figure 3E).”
Quote in the paperSubstantial claim- Rests on an assumption: STING-/- mice lack functional host STING signaling.
- Findingown data
A significant inhibition in RMS 76-9 lung metastases was observed in STING-/- mice bearing RMS 76-9STINGwt tumor.
“We also observed a significant inhibition in RMS 76-9 lung metastases in the same experimental group (figure 5B,C).”
Quote in the paperSubstantial claim- Rests on an assumption: STING-/- mice lack functional host STING signaling.
- Findingown data
Cryoablation of RMS 76-9STINGwt tumor in wild-type mice produced robust systemic immunity to suppress distant lung metastasis.
“but also produced a robust systemic immunity to suppress distant lung metastasis (figure 4B,C).”
Quote in the paperSubstantial claim - Findingown data
Cryoablation of RMS 76-9 tumors significantly increases Ifn-β mRNA transcript and protein secretion in tumor-infiltrating DCs.
“Tumors treated with cryoablation induced a significant increase in Ifn-β mRNA transcript (figure 3B) and protein secretion (figure 3C) in tumor-infiltrating DCs.”
Quote in the paperSubstantial claim - Findingown data
A significant tumor growth inhibition was observed when cryoablation was carried out in STING-/- mice bearing RMS 76-9STINGwt tumor.
“a significant tumor growth inhibition was again observed when cryoablation was carried out in STING-/- mice bearing RMS 76-9STINGwt tumor (figure 5A).”
Quote in the paperSubstantial claim- Rests on an assumption: STING-/- mice lack functional host STING signaling.
- Findingown data
Cell lysates from cryoablated RMS 76-9 cells stimulated maturation of CD11c+ DCs, as evidenced by a significant increase in the frequency of co-cultured BMDCs expressing CD86, CD40 and MHC II compared with BMDCs co-cultured with non-cryoablated RMS 76-9 cells.
“Cell lysates from cryoablated RMS 76-9 cells were able to stimulate the maturation of CD11c+ DCs, as evidenced by a significant increase in the frequency of co-cultured BMDCs expressing CD86, CD40 and MHC II, as compared with BMDCs co-cultured with non-cryoablated RMS 76-9 cells (figure 2A).”
Quote in the paperSubstantial claim - Findingown data
The basal level of various lymphocyte compartments was significantly reduced or trending toward a reduction in C57BL/6 mice bearing RMS 76-9STING-/- tumors compared with RMS 76-9STINGwt.
“the basal level of various lymphocyte compartments was significantly reduced or trending toward a reduction in C57BL/6 mice bearing RMS 76-9STING-/- tumors as compared with RMS 76-9STINGwt.”
Quote in the paperSubstantial claim - Findingown data
Other forms of RMS 76-9 cell death, such as radiation and chemotherapy, resulted in similar levels of MHC II and CD86 expression on co-cultured BMDCs as compared with non-cryoablated RMS76-9 cells.
“Other forms of RMS 76-9 cell death, such as those induced by radiation and chemotherapy, resulted in similar levels of MHC II and CD86 expression on co-cultured BMDCs as compared with non-cryoablated RMS76-9 cells (online supplemental figure S2).”
Quote in the paperSubstantial claim - Findingown data
Co-culture of in vitro cryo-treated RMS 76-9 cells with BMDCs from STING-/- mice resulted in complete absence of Ifn-β transcription compared with BMDCs from wild-type mice.
“We co-cultured in vitro cryo-treated RMS 76-9 cells with BMDCs derived from STING-/- mice, and observed a complete absence of Ifn-β transcription as compared with BMDCs from wild-type mice (figure 3D)”
Quote in the paperSubstantial claim - Findingown data
The differences among Foxp3+ CD4+ cells, NK cells, CD11c+ myeloid cells and CD11b+ myeloid cells were also lost in the context of STING-/- mice.
“The differences among Foxp3+ CD4+ cells, natural killer (NK) cells, CD11c+ myeloid cells and CD11b+ myeloid cells were also lost in the context of STING-/- mice.”
Quote in the paperSubstantial claim- Rests on an assumption: STING-/- mice lack functional host STING signaling.
- Findingown data
RMS 76-9STINGwt primary tumor exhibited a robust response to cryoablation despite the absence of host STING signaling.
“RMS 76-9STINGwt primary tumor again exhibited a robust response to cryoablation despite the absence of host STING signaling (figure 8E, yellow)”
Quote in the paperSubstantial claim- Rests on an assumption: STING-/- mice lack functional host STING signaling.
- Findingown data
No significant differences in the level of cell death following cryoablation in vivo within the non-necrotic tumor zone 3 days following cryoablation, as assessed by Caspase-3+ and TUNEL+ tumor cells.
“we assessed the level of Caspase-3+ and TUNEL+ tumor cells in vivo within the non-necrotic tumor zone 3 days following cryoablation, and found no significant differences in the level of cell death following cryoablation (online supplemental figure S9D,E).”
Quote in the paperSubstantial claim - Findingown data
Comparing lung metastatic lesions following cryoablation, the percentage of RMS 76-9 STING-/- E2-Crimson cells in the lung was proportionally higher than that of RMS 76-9 STINGwt mNeonGreen cells.
“Comparing lung metastatic lesions in the lungs following cryoablation, the percentage of RMS 76-9 STING-/- E2-Crimson cells in the lung was proportionally higher than that of RMS 76-9 STINGwt mNeonGreen cells (online supplemental figure S10F)”
Quote in the paperSubstantial claim - Findingown data
Cryoablation of primary RMS 76-9STINGwt tumor led to a significant reduction of the advanced, untreated secondary tumor.
“cryoablation of primary RMS 76-9STINGwt tumor led to a significant reduction of the advanced, untreated secondary tumor (figure 8C, yellow).”
Quote in the paperSubstantial claim - Findingown data
A slightly enhanced susceptibility of STING-/- cells to cell death both in vitro and in vivo was observed.
“we also observed a slightly enhanced susceptibility of these cells to cell death both in vitro and in vivo.”
Quote in the paperSubstantial claim - Findingown data
This abscopal effect on secondary RMS 76-9STINGwt was lost on cryoablation of RMS 76-9STING-/- primary tumor.
“this abscopal effect on secondary RMS 76-9STINGwt was lost on cryoablation of RMS 76-9STING-/- primary tumor (figure 8C, black).”
Quote in the paperSubstantial claim - Findingown data
The absence of STING in either the tumor cells or the host alone partially suppressed tumor growth.
“the absence of STING in either the tumor cells (figure 9A, black) or the host (figure 9B, yellow) alone partially suppressed tumor growth”
Quote in the paperSubstantial claim - Findingown data
CD8+ T cells were absolutely essential for the in vivo antitumor efficacy.
“CD8+ T cells were absolutely essential for the in vivo antitumor efficacy.”
Quote in the paperSubstantial claim - Findingown data
No significant differences in necroptosis resulting from cryoablation between the two cell lines as assessed by phosphorylation of MLKL.
“we did not observe any significant differences in necroptosis resulting from cryoablation between the two cell lines as assessed by phosphorylation of MLKL (online supplemental figure S9A).”
Quote in the paperSubstantial claim - Findingown data
A slight baseline proliferative advantage of STING-/- tumors was observed.
“Although we did observe a slight baseline proliferative advantage of STING-/- tumors, we also observed a slightly enhanced susceptibility of these cells to cell death both in vitro and in vivo.”
Quote in the paperNot a substantial claim - Findingown data
Genetic deletion of Tmem173 within RMS 76-9 completely abrogated cryoablation-induced IFN-β upregulation, indicating a STING dependency of this process within RMS 76-9.
“Genetic deletion of Tmem173 within RMS 76-9 completely abrogated cryoablation-induced IFN-β upregulation, indicating a STING dependency of this process within RMS 76-9.”
Quote in the paperSubstantial claim - Findingown data
No significant difference in the growth of STINGwt and STING-/- tumors in vivo at baseline was observed.
“We did not observe any significant difference in the growth of STINGwt and STING-/- tumors in vivo at baseline.”
Quote in the paperSubstantial claim - Findingown data
Cryoablation had no effect on the proportion of RMS 76-9 STING-/- E2-Crimson tumor cell metastases in the lung tissue compared with non-cryoablated controls.
“while cryoablation had no effect on the proportion of RMS 76-9 STING-/- E2-Crimson tumor cell metastases in the lung tissue compared with non-cryoablated controls (online supplemental figure S10E).”
Quote in the paperSubstantial claim - Findingown data
Both tumors showed similar growth suppression when subjected to various cryoablation treatment regimens in vitro.
“both tumors showed similar growth suppression when subjected to various cryoablation treatment regimens in vitro (online supplemental figure S8C).”
Quote in the paperSubstantial claim - Findingown data
No significant differences in cleaved Caspase-3 and Gasdermin D activation following cryoablation in vitro by western blot analysis.
“we failed to observe any significant differences in cleaved Caspase-3 and Gasdermin D activation following cryoablation in vitro by western blot analysis (data not shown).”
Quote in the paperSubstantial claim - Findingown data
An abscopal effect was observed in the co-injection model.
“This conclusion was further supported by the observed abscopal effect in the co-injection model.”
Quote in the paperSubstantial claim - Findingown data
In STING-/- mice, the tumor reduction efficacy of cryoablation in the primary tumor was completely lost in the context of RMS 76-9STING-/- tumor.
“The tumor reduction efficacy of cryoablation in the primary tumor was completely lost in the context of RMS 76-9STING-/- tumor (figure 8E, black).”
Quote in the paperSubstantial claim- Rests on an assumption: STING-/- mice lack functional host STING signaling.
- Findingown data
Cryoablation of primary RMS 76-9STINGwt tumor led to a significant reduction of the advanced, untreated secondary tumor in the complete absence of host STING signaling.
“cryoablation of primary RMS 76-9STINGwt tumor led to a significant reduction of the advanced, untreated secondary tumor (figure 8F, yellow) in the complete absence of host STING signaling.”
Quote in the paperSubstantial claim- Rests on an assumption: STING-/- mice lack functional host STING signaling.
- Findingown data
Analysis of different phases of apoptotic cell death over a 3-day time span revealed that RMS 76-9STINGwt have a higher percentage of live tumor cells, while RMS 76-9STING-/- exhibited more early and late apoptotic markers across time and cryoablation regimens.
“analysis of different phases of apoptotic cell death over a 3-day time span revealed that RMS 76-9STINGwt have a higher percentage of live tumor cells, while RMS 76-9STING-/- exhibited more early and late apoptotic markers across time and cryoablation regimens (online supplemental figure S8D-F).”
Quote in the paperSubstantial claim - Findingown data
This differential STING expression between tumor and mononuclear cells was lost in the higher grade and more advanced stage tumors.
“this differential STING expression between tumor and mononuclear cells was lost in the higher grade and more advanced stage tumors (online supplemental figure S11F)”
Quote in the paperNot a substantial claim - Findingown data
Tmem173 and Tbk1 transcript expression in RMS were lower in metastatic and relapsed patients when compared with primary tumor at diagnosis.
“Tmem173 and Tbk1 transcript expression in RMS were lower in metastatic and relapsed patients when compared with primary tumor at diagnosis (online supplemental figure S11B)”
Quote in the paperSubstantial claim - Findingown data
Mononuclear cells expressed higher levels of STING in the TME than the tumor.
“we found that mononuclear cells expressed higher levels of STING in the TME than the tumor (online supplemental figure S11E).”
Quote in the paperNot a substantial claim - Findingown data
Increased production of IFN-β by DCs after tumor cryoablation in vitro and in vivo.
“observed increased production of IFN-β by DCs after tumor cryoablation in vitro and in vivo.”
Quote in the paperNot a substantial claim - Findingown data
CD4+ T cells partially contributed to immune-mediated tumor regression following cryoablation.
“While CD4+ T cells partially contributed to this immune-mediated tumor regression following cryoablation, CD8+ T cells were absolutely essential for the in vivo antitumor efficacy.”
Quote in the paperNot a substantial claim - Findingown data
IFN-β production by APCs in our model is STING-dependent.
“we used BMDCs from STING-/- mice to demonstrate the STING dependency of IFN-β production by APCs in our model.”
Quote in the paperSubstantial claim - Findingown data
Increased IFN-β in the TME following tumor cryoablation.
“Here, we showed increased IFN-β in the TME following tumor cryoablation, and observed increased production of IFN-β by DCs after tumor cryoablation in vitro and in vivo.”
Quote in the paperSubstantial claim - Findingown data
DMXAA administration effectively reduced RMS 76-9STINGwt growth in C57BL/6 mice.
“while DMXAA administration effectively reduced RMS 76-9STINGwt growth in C57BL/6 mice (figure 9A, yellow)”
Quote in the paperSubstantial claim - Findingown data
This abscopal effect on secondary RMS 76-9STINGwt was completely abrogated on cryoablation of RMS 76-9STING-/- primary tumor.
“this abscopal effect on secondary RMS 76-9STINGwt was completely abrogated on cryoablation of RMS 76-9STING-/- primary tumor (figure 8F, black).”
Quote in the paperSubstantial claim - Findingown data
Successful cryoablation therapies against advanced tumor growth require the adaptive immune response.
“Using the RMS 76-9 sarcoma tumor model, we demonstrated that successful cryoablation therapies against advanced tumor growth requires the adaptive immune response, as cryoablation failed to control primary tumor growth in immune-deficient mice resulting from rapid local recurrence and metastasis following cryoablation.”
Quote in the paperSubstantial claim - Findingown data
A complete absence of STING in both tumor cells and the host completely abolished in vivo antitumor efficacy of STING agonism.
“while a complete absence of STING in both tumor cells and the host completely abolished in vivo antitumor efficacy of STING agonism (figure 9B, black).”
Quote in the paperSubstantial claim - Findingown data
A significant decrease in the percentage of RMS 76-9 STINGwt mNeonGreen cell subpopulation was observed in the lungs of mice treated with cryoablation compared with sham-ablated control mouse lung.
“A significant decrease in the percentage of RMS 76–9 STINGwt mNeonGreen cell subpopulation was observed in the lungs of mice treated with cryoablation as compared with sham-ablated control mouse lung (online supplemental figure S10D)”
Quote in the paperSubstantial claim - Findingown data
Patient-derived data showed a wide variation in the expression level of STING pathway components in pediatric and adolescent and young adult (AYA) cancers.
“These patient-derived data showed a wide variation in the expression level of STING pathway components in pediatric and adolescent and young adult (AYA) cancers.”
Quote in the paperSubstantial claim - Findingown data
Partial blunting of tumor growth was consistently observed in the complete absence of host STING signaling.
“we consistently observed a partial blunting of tumor growth in the complete absence of host STING signaling.”
Quote in the paperSubstantial claim - Findingown data
IFN-β levels remained at baseline in cryoablated STING-/- RMS TME even in wild-type mice.
“whereas INF-β levels remained at baseline in cryoablated STING-/- RMS TME even in wild-type mice.”
Quote in the paperSubstantial claim - Findingown data
Elevated IFN-β levels following cryoablation of RMS STINGwt irrespective of host STING status.
“Importantly, when analyzing chemokine and cytokine productions within TME, we found elevated IFN-β levels following cryoablation of RMS STINGwt irrespective of host STING status”
Quote in the paperSubstantial claim - Findingown data
Increases in several chemokines and cytokines (eg, CXCL9, CXCL10, CCL6, CCL8, CCL9/10, IL-16, and CXCL2) in the RMS STINGwt TME following cryoablation even within the context of a wild-type mouse.
“Indeed, chemokine and cytokine arrays of various TME revealed increases in several chemokines and cytokines (eg, CXCL9, CXCL10, CCL6, CCL8, CCL9/10, IL-16, and CXCL2) in the RMS STINGwt TME following cryoablation even within the context of a wild-type mouse.”
Quote in the paperSubstantial claim - Interpretationown data
Lung metastasis following cryoablation is critically dependent on a functioning tumor cell-intrinsic STING signaling pathway.
“we show that local tumor control, lung metastasis, and the abscopal effect on distant tumor are all critically dependent on a functioning tumor cell-intrinsic STING signaling pathway, which induces inflammatory chemokine and cytokine responses in the cryoablated TME.”
Quote in the paperSubstantial claim - Interpretationown data
Local tumor control following cryoablation is critically dependent on a functioning tumor cell-intrinsic STING signaling pathway.
“we show that local tumor control, lung metastasis, and the abscopal effect on distant tumor are all critically dependent on a functioning tumor cell-intrinsic STING signaling pathway, which induces inflammatory chemokine and cytokine responses in the cryoablated TME.”
Quote in the paperSubstantial claim - Interpretationown data
Tumor cell-intrinsic STING pathway is a critical component underlying the effectiveness of cryoablation.
“Tumor cell-intrinsic STING pathway is a critical component underlying the effectiveness of cryoablation”
Quote in the paperSubstantial claim - Interpretationown data
Cryoablation efficacy is dependent on adaptive immunity.
“The results show that cryoablation efficacy is dependent on both adaptive immunity and the STING signaling pathway.”
- Also stated in: § Cryoablation promotes RMS regression through adaptive immunity · hedged
“indicating that the adaptive T-cell response was required for the observed therapeutic efficacy of cryoablation in vivo (figure 1B).”
- Also stated in: § Cryoablation promotes RMS regression through adaptive immunity · boosted
“Taken together, these data underscore the importance of host adaptive T-cell immunity in mediating a seemingly curative antitumor effect using a cryoablation procedure that proved to be only sublethal against the tumor without a functional adaptive T-cell immunity in this model.”
Quote in the paperSubstantial claim - Also stated in: § Cryoablation promotes RMS regression through adaptive immunity · hedged
- Interpretationown data
The reliance on tumor cell-intrinsic STING extends beyond cryoablation to include intratumoral STING agonist therapy.
“This reliance extends beyond cryoablation to include intratumoral STING agonist therapy.”
Quote in the paperSubstantial claim - Interpretationown data
The abscopal effect on distant tumor following cryoablation is critically dependent on a functioning tumor cell-intrinsic STING signaling pathway.
“we show that local tumor control, lung metastasis, and the abscopal effect on distant tumor are all critically dependent on a functioning tumor cell-intrinsic STING signaling pathway, which induces inflammatory chemokine and cytokine responses in the cryoablated TME.”
Quote in the paperSubstantial claim - Interpretationown data
Tumor cell-intrinsic STING signaling induces inflammatory chemokine and cytokine responses in the cryoablated TME.
“we show that local tumor control, lung metastasis, and the abscopal effect on distant tumor are all critically dependent on a functioning tumor cell-intrinsic STING signaling pathway, which induces inflammatory chemokine and cytokine responses in the cryoablated TME.”
Quote in the paperSubstantial claim - Interpretationown data
Cryoablation efficacy is dependent on the STING signaling pathway.
“The results show that cryoablation efficacy is dependent on both adaptive immunity and the STING signaling pathway.”
Quote in the paperSubstantial claim - Interpretationown data
Expression of STING-related signaling components may serve as a potential therapy response biomarker.
“suggests that expression of STING-related signaling components may serve as a potential therapy response biomarker.”
Quote in the paperSubstantial claim - Interpretationown data
The STING signaling pathway is essential for tumor cryoablation-induced type I IFN production in DCs.
“suggesting that the STING signaling pathway is essential for tumor cryoablation-induced type I IFN production in DCs.”
Quote in the paperSubstantial claim - Interpretationown data
Tumor cryoablation induces APC maturation toward immune stimulating and antitumor phenotypes.
“Our results suggest that tumor cryoablation induces APC maturation toward immune stimulating and antitumor phenotypes.”
Quote in the paperSubstantial claim - Interpretationown data
This provides a cellular mechanism of partial cryoablation efficacy afforded by cryoablation of RMS 76-9STINGwt.
“thereby providing a cellular mechanism of partial cryoablation efficacy afforded by cryoablation of RMS 76-9STINGwt (figure 5A).”
Quote in the paperSubstantial claim- Rests on an assumption: STING-/- mice lack functional host STING signaling.
- Interpretationown data
The increase in lung metastases suggests ineffective systemic immunity.
“suggesting ineffective systemic immunity.”
Quote in the paperSubstantial claim - Study design and conductown data
RMS 76-9 cells have an intact STING signaling pathway.
“we validated that there was an intact STING signaling pathway in RMS 76-9”
Quote in the paperSubstantial claim - Interpretationreasoning
There is a generalized vital role of tumor cell-intrinsic STING in generating effective antitumor immunity in other ICD-inducing cancer therapies.
“suggesting a generalized vital role of tumor cell-intrinsic STING in generating effective antitumor immunity in other ICD-inducing cancer therapies.”
Quote in the paperSubstantial claim - Interpretationreasoning
This reflects a decrease in overall STING expression, supported by the Tmem173 transcript expression profile of the PeCan dataset.
“reflecting a decrease in overall STING expression, which is supported by the Tmem173 transcript expression profile of the PeCan dataset.”
Quote in the paperNot a substantial claim - Interpretationown data
Cryoablation boosted tumor antigen presentation by DCs and T cell activation and recruitment through an ICD-mediated in situ vaccine effect.
“These findings support the view that cryoablation boosted tumor antigen presentation by DCs and T cell activation and recruitment through an ICD-mediated in situ vaccine effect.”
Quote in the paperSubstantial claim - Interpretationown data
Tumor cell-intrinsic STING signaling critically impacts the abscopal effect of the non-cryoablated advanced distant tumors as induced by cryoablation of the primary tumor.
“Taken together, tumor cell-intrinsic STING signaling critically impacts the abscopal effect of the non-cryoablated advanced distant tumors as induced by cryoablation of the primary tumor.”
Quote in the paperSubstantial claim - Interpretationown data
Intrinsic differences of cell proliferation or various forms of cell death between STINGwt and STING-/- tumors cannot explain the observed therapeutic efficacy of cryoablation.
“Our data suggest that intrinsic differences of cell proliferation or various forms of cell death between STINGwt and STING-/- tumors cannot explain our observed therapeutic efficacy of cryoablation.”
Quote in the paperSubstantial claim - Interpretationreasoning
The vital contribution of tumor-intrinsic STING signaling to generate effective local immune TME extends beyond cryoablation into other therapeutic modalities including direct intratumoral injection of STING agonist, DMXAA.
“Importantly, the vital contribution of tumor-intrinsic STING signaling to generate effective local immune TME extends beyond cryoablation into other therapeutic modalities including direct intratumoral injection of the STING agonist, DMXAA”
Quote in the paperSubstantial claim - Interpretationown data
This supports the observation in the RMS 76-9 model that tumor cell-intrinsic STING is critical for antitumor immunity.
“supporting our observation in the RMS 76-9 model that tumor cell-intrinsic STING is critical for antitumor immunity.”
Quote in the paperSubstantial claim - Interpretationcitation
Enhanced T cell survival in tumor-bearing STING-/- mice may be a contributing factor to the efficacy of cryoablation of RMS 76-9STINGwt in STING-/- mice.
“Beyond RMS 76-9-intrinsic STING signaling directly contributing to the clinical efficacy of cryoablation observed in STING-/- mice, a contributing factor may be the enhanced T cell survival in tumor-bearing STING-/- mice”
Quote in the paperNot a substantial claim - Interpretationown data
Our current data argue for a critical role of functional tumor cell-intrinsic STING signaling as a major determinant in cryoablation-induced antitumor immunity activation and clinical responses.
“Remarkably, our current data argue for a heretofore unappreciated but critical role of functional tumor cell-intrinsic STING signaling as a major determinant in cryoablation-induced antitumor immunity activation and clinical responses”
Quote in the paperSubstantial claim - Interpretationown data
A myeloid cell-mediated mechanism contributes to the therapeutic effects of cryoablation.
“Although these findings support the involvement of a myeloid cell-mediated mechanism that contributes to the therapeutic effects of cryoablation”
Quote in the paperSubstantial claim - Interpretationreasoning
A functional tumor STING signaling pathway serves as the dominant determinant of therapy response.
“while a functional tumor STING signaling pathway serves as the dominant determinant of therapy response.”
Quote in the paperSubstantial claim - Interpretationown data
We provided preclinical proof of concept that tumor-intrinsic STING signaling contributes critically to cryoablation-mediated tumor suppression in vivo in at least three different tumor models, although with varying degree of efficacy.
“We provided preclinical proof of concept that tumor-intrinsic STING signaling contributes critically to cryoablation-mediated tumor suppression in vivo in at least three different tumor models, although with varying degree of efficacy.”
Quote in the paperSubstantial claim - Interpretationreasoning
Tumor cell-intrinsic STING-related signaling expression is a biomarker of potential therapy responses in cryoablation.
“Our results highlight the tumor cell-intrinsic STING-related signaling expression as a biomarker of potential therapy responses in cryoablation”
Quote in the paperSubstantial claim - Interpretationown data
The tumor cell-intrinsic STING pathway is a critical contributor to both local response and the abscopal effect in cryoablation and local STING agonist therapy.
“In conclusion, we identified the tumor cell-intrinsic STING pathway as a critical contributor to both local response and the abscopal effect in cryoablation and local STING agonist therapy.”
Quote in the paperSubstantial claim
- Classified as probably not a substantial claim. 24
- May combine two claims. 27
- The quote only partly states this claim. 1
Classified as probably not a substantial claim. May combine two claims.
PremisecitationClinical response to cryoablation is highly variable and lacks a reliable biomarker predicting a beneficial therapeutic outcome.
“Despite these theoretical advantages, clinical response to cryoablation is highly variable and suffers from the absence of a reliable biomarker that predicts a beneficial therapeutic outcome of this approach.15”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [15] Baust, 2014, Mechanisms of Cryoablation: clinical consequences on malignant tumors, Cryobiology source
The Introduction describes inherent variability in cryoablative applications, and the Summary notes persistent disease after freezing. These passages partly support variable outcomes, but they do not establish that clinical response is highly variable or state that a reliable predictive biomarker is absent. Page numbers are unavailable in our copy. (LLM, conf=0.83)
Experimental — accuracy not yet measured
Classified as probably not a substantial claim.
PremisecitationRecent evidence suggests that tumor cell-intrinsic STING is critical to the production of type I IFNs and promotion of CD8+ T cell activation via enhancing the function of APCs.
“As recent evidence suggests that tumor cell-intrinsic STING is critical to the production of type I IFNs and promotion of CD8+ T cell activation via enhancing the function of APCs,33”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [33] source
The Results sections on type I IFN activation and epitope-specific T cell activation report that STING-deficient dMLH1 tumor cells lose type I IFN signaling and are less able to support dendritic-cell-mediated CD8+ T cell priming. The evidence is specific to MLH1-deficient or dMMR tumor models; the claim does not retain that condition and could be read as applying to tumor cells generally. (LLM, conf=0.82)
Experimental — accuracy not yet measured
Probably not a substantial claim: may not pass S1 (asserted).
PremisecitationIt has been proposed that tumor cell-intrinsic STING enhances tumor immunogenicity by increasing immune cell activation and triggering tumor cell regression.
“it has been proposed that tumor cell-intrinsic STING enhances tumor immunogenicity by increasing immune cell activation and triggering tumor cell regression.47–49”
Quote in the paperNot a substantial claim3 of 3 sources checked- cites [47] source
The Results section ('Intratumoral STING pathway activation is required for olaparib-induced T cell recruitment and anti-tumor efficacy'; page not supplied) links tumor-cell STING activation to CD8+ T-cell recruitment and activation, and reports reduced tumor burden with olaparib when tumor-cell STING is intact. It does not establish tumor regression, and its findings concern PARP-inhibitor-treated, BRCA-deficient breast cancer models rather than tumor-cell STING activation generally. (LLM, conf=0.83)
Experimental — accuracy not yet measured - cites [48] source
- cites [49] Yang, 2021, Zbp1-MLKL Necroptotic signaling potentiates radiation-induced antitumor immunity via Intratumoral STING pathway activation, Sci Adv source
The Results section reports that tumors lacking STING had poorer control after radiation and fewer activated, tumor-specific CD8+ T cells, supporting a role for tumor cell–intrinsic STING in antitumor immunity. The evidence is specific to radiation-treated tumors; it reports tumor control rather than explicitly showing that STING triggers tumor regression more generally. No page number is available in our copy. (LLM, conf=0.83)
Experimental — accuracy not yet measured
Classified as probably not a substantial claim.
PremisecitationDifferent tumor models have shown variability in their responses to STING signaling.
“As different tumor models have shown variability in their responses to STING signaling,66”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [66] Kim, 2023, Brief report: STING expressed in tumor and non-tumor compartments has distinct roles in regulating anti-tumor immunity, Cancer Immunol Immunother source
May combine two claims.
Findingown dataIn post-cryoablated RMS 76-9STINGwt TME compared with RMS 76-9STING-/- TME in wild-type mice, there was a significant increase in total CD4+ T cells expressing IFN-γ and GZMB, NK cells, GZMB expression in CD8+ T cells, and Foxp3+ CD4+ cells.
“we observed a significant increase in the total CD4+ T cells expressing IFN-γ (figure 4H) and granzyme B (GZMB; figure 4J),60–65 NK cells (figure 4N), and the amount of GZMB expression in CD8+ T cells (figure 4L) in the post-cryoablated RMS 76-9STINGwt TME as compared with RMS 76-9STING-/- TME in wild-type mice, as was Foxp3+ CD4+ cells (figure 4M).”
Quote in the paperSubstantial claim6 of 6 sources checked- cites [60] Knelson, 2022, Activation of tumor-cell STING primes NK-cell therapy, Cancer Immunol Res source
The Results section on dynamic scRNA-seq of MPM explants identifies granzyme-positive T cells and NK cells, but it does not report the claimed increases after cryoablation. Searches for RMS 76-9, cryoablation, and the STING-wild-type versus STING-knockout comparison found no passage addressing that experiment in our copy. (LLM, conf=0.75)
Experimental — accuracy not yet measured - cites [61] Berger, 2022, STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models, Proc Natl Acad Sci U S A source
The Results section, “STING Activation in Intracranial GBM Models Drives Innate Immune Cell Infiltration” (page unavailable), reports increased NK-cell infiltration after STING-agonist treatment. It studies glioblastoma models, not cryoablated RMS 76-9 tumors, and does not support the stated RMS comparison or the specific IFN-γ, granzyme B, and Foxp3+ CD4+ cell increases. (LLM, conf=0.83)
Experimental — accuracy not yet measured - cites [62] Śledzińska, 2020, Regulatory T cells restrain Interleukin-2- and Blimp-1-dependent acquisition of cytotoxic function by Cd4+ T cells, Immunity source
- cites [63] source
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured - cites [64] source
Split into 2 atoms — 1 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured - cites [65] Takeuchi, 2017, Cd4 CTL, a cytotoxic subset of Cd4(+) T cells, their differentiation and function, Front Immunol source
The Introduction says cytotoxic CD4+ T cells can contain granzyme B, and the Differentiation of CD4 CTL section discusses IFN-γ production. Neither section reports the cited increase after cryoablation, the RMS 76-9 STING comparison, or the NK, CD8+, and Foxp3+ findings; those are presented in the citing sentence as its authors’ own observations. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Classified as probably not a substantial claim.
PremisecitationPrevious studies have suggested that the tumor cell-intrinsic STING pathway may be essential in triggering antitumor immunity in other contexts.
“Previous studies have suggested that the tumor cell-intrinsic STING pathway may be essential in triggering antitumor immunity in other contexts.47–49”
Quote in the paperSubstantial claim3 of 3 sources checkedClassified as probably not a substantial claim.
PremisecitationThe current dogma dictates that the host-derived STING pathway is the converging critical responder.
“a finding that is in sharp contrast to the current dogma which dictates that host-derived STING pathway is the converging critical responder.79–81”
Quote in the paperSubstantial claim3 of 3 sources checked- cites [79] Ni, 2022, T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by Upregulating Foxp3 transcription in Cervical cancer, J Immunother Cancer source
The Introduction (page unavailable) says STING signaling in immune cells is needed for type I IFN-dependent T-cell priming and NK-cell cytotoxicity, supporting an important role for host-cell STING in antitumor immunity. It does not establish the broader claim that host-derived STING is the converging critical responder; the Discussion (page unavailable) also describes a distinct role for T-cell-intrinsic STING. (LLM, conf=0.78)
Experimental — accuracy not yet measured - cites [80] Luo, 2022, Transcription-independent regulation of STING activation and innate immune responses by Irf8 in monocytes, Nat Commun source
The Introduction describes STING as critical to innate immune responses and notes that the cGAS–STING pathway is involved in anti-tumor immunity. The Discussion also links STING to cancer prognosis. Neither section establishes the more specific claim that host-derived STING is the converging critical responder. (LLM, conf=0.82)
Experimental — accuracy not yet measured - cites [81] Kabashima, 2022, cGAS-STING signaling encourages immune cell overcoming of fibroblast barricades in Pancreatic cancer, Sci Rep source
The Introduction (page unavailable) describes cGAS-STING as a crucial regulator of tumor immunity, supporting the pathway’s general importance. It does not identify host-derived STING as the converging critical responder. The Discussion (page unavailable) reports lower recruitment of CD8+ T cells toward cancer cells in stromal-STING-dominant cases than in cases with cancer-cell cGAS-STING expression, while cautioning that there were too few stromal-dominant cases for firm conclusions. (LLM, conf=0.78)
Experimental — accuracy not yet measured
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationRecurrent, refractory and metastatic RMS represents one of the persistent clinical therapeutic challenges and unmet clinical need, with improvement in 5-year survival experiencing one of the smallest increases of all pediatric and AYA cancers.
“of which recurrent, refractory and metastatic RMS represents one of the persistent clinical therapeutic challenges and unmet clinical need,88–90 with improvement in 5-year survival experiencing one of the smallest increases of all pediatric and AYA cancers.91–95”
Quote in the paperNot a substantial claim2 of 8 sources checked- cites [88] source
- cites [89] source
- cites [90] source
- cites [91] source
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured - cites [92] source
- cites [93] source
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured - cites [94] source
- cites [95] Raney, 1988, Disease patterns and survival rate in children with metastatic soft-tissue sarcoma, A Report from the Intergroup Rhabdomyosarcoma Study (IRS)-I Cancer source
Probably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataSurveys of gene expression databases and tissue microarrays of clinical tumor samples revealed a wide spectrum of expressions among STING-related signaling components.
“Additionally, surveys of gene expression databases and tissue microarrays of clinical tumor samples revealed a wide spectrum of expressions among STING-related signaling components.”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataCryoablation effectively reduced the size of established RMS 76-9 tumor mass and suppressed local recurrence over the following 2 weeks.
“Cryoablation effectively reduced the size of the established tumor mass while suppressing the rate of local recurrence over the following 2 weeks (figure 1A).”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataThere were clear differences in the TME expression profiles for each treatment group as shown by the number of events per cluster in density plots.
“There were clear differences in the TME expression profiles for each treatment group as shown by the number of events per cluster in each of the density plots (figure 4E).”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataThe effect of cryoablation was greatly reduced in nude mice, which all succumbed to disease days after the last tumor measurement on day 21.
“the effect of cryoablation was greatly reduced in nude mice which all succumb to disease days after the last tumor measurement on day 21”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataCryoablation of M3-9-MSTINGwt and KPC1242STINGwt resulted in significantly reduced tumor burden in C57BL/6 mice, while the same intervention was ineffectual against M3-9-MSTING-/- and KPC1242STING-/- tumors, even in C57BL/6 mice with intact host STING signaling pathways.
“Similar to RMS 76-9, cryoablation of M3-9-MSTINGwt and KPC1242STINGwt resulted in significantly reduced tumor burden in C57BL/6 mice mice, while the same intervention was ineffectual against M3-9-MSTING-/- and KPC1242STING-/- tumors, even in C57BL/6 mice with intact host STING signaling pathways (figure 6).”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataCaspase-3 staining data suggest a slightly higher basal level of Caspase-3+ tumor cells among RMS 76-9STING-/- tumors.
“our Caspase-3 staining data suggest that there appears to be a slightly higher basal level of Caspase-3+ tumor cells among RMS 76-9STING-/- tumors (online supplemental figure S9E)”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataTreatment with DMXAA impaired RMS 76-9STINGwt growth in a dose-dependent manner, while RMS 76-9STING-/- was not affected until a high DMXAA dose range.
“Treatment with DMXAA impaired RMS 76-9STINGwt growth in a dose-dependent manner, while 76-9STING-/- was not affected until a high DMXAA dose range (online supplemental figure S8B).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataCryoablation of RMS 76-9STINGwt was efficacious in suppressing primary tumor growth and preventing lung metastasis regardless of whether the tumor-bearing hosts express functional STING in all tissue compartments.
“Surprisingly, cryoablation of RMS 76-9STINGwt was efficacious in suppressing primary tumor growth, as well as preventing lung metastasis regardless of whether or not the tumor-bearing hosts express functional STING in all tissue compartments.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe tumor reduction efficacy of cryoablation in the primary tumor was completely lost in the context of RMS 76-9STING-/- tumor, while RMS 76-9STINGwt primary tumor exhibited a robust response.
“The tumor reduction efficacy of cryoablation in the primary tumor was completely lost in the context of RMS 76-9STING-/- tumor (figure 8B, black), while RMS 76-9STINGwt primary tumor exhibited a robust response (figure 8B, yellow)”
Quote in the paperSubstantial claimMay combine two claims.
FindingcitationCryoablation enhanced the infiltration of total CD45+ cells and functional CD8+ T cells and increased the expression of co-stimulatory molecules on DCs.
“Cryoablation enhanced the infiltration of total CD45+ cells and functional CD8+ T cells82 and increased the expression of co-stimulatory molecules on DCs.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [82] source
May combine two claims.
Findingown dataNeither tumor-bearing C57BL/6 nor STING-/- mice benefited from cryoablation when treating RMS 76-9STING-/- tumor, and experienced rampant lung metastasis.
“In sharp contrast to RMS 76-9STINGwt tumor, however, neither tumor-bearing C57BL/6 nor STING-/- mice benefited from cryoablation when treating RMS 76-9STING-/- tumor, and experienced rampant lung metastasis.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataLive RMS 76-9 maintains a functional STING signaling pathway and serves as a major source of IFN-β after STING activation either by co-culturing with cryoablated tumor or DMXAA.
“In addition to being a potential source of CDN/cGAMP, live RMS 76-9 maintains a functional STING signaling pathway and serves as a major source of IFN-β after STING activation either by co-culturing with cryoablated tumor or DMXAA.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataChemokine and cytokine protein production was not significantly changed before and after cryoablation in STING-/- tumor TME, even though the host stroma contains a functional STING signaling pathway.
“chemokine and cytokine protein production was not significantly changed before and after cryoablation in STING-/- tumor TME, even though the host stroma contains a functional STING signaling pathway (figure 7B–D).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataCryoablation failed to control primary tumor growth in immune-deficient mice, resulting from rapid local recurrence and metastasis following cryoablation.
“as cryoablation failed to control primary tumor growth in immune-deficient mice resulting from rapid local recurrence and metastasis following cryoablation.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataDownstream signaling molecule activation in the tumor-intrinsic STING signaling pathway requires time (up to 4 hours) and the effect can be transient.
“Our investigation into tumor-intrinsic STING signaling pathway kinetics suggests that downstream signaling molecule activation requires time (up to 4 hours) and the effect can be transient.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingnone givenOur survey of available pediatric tumor databases revealed heterogeneous expression patterns among pediatric cancers.
“Our survey of available pediatric tumor databases revealed a heterogeneous expression patterns among pediatric cancers”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataThe abscopal tumor remained sizeable and many progressed over time in the co-implantation tumor model.
“Despite the overall improvement in the abscopal efficacy in our co-implantation tumor model, the abscopal tumor remained sizeable and many progressed over time”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataLittle change in the cytokine and chemokine arrays were observed in the RMS STING-/- TME following cryoablation, despite the host being fully capable of responding to STING activation.
“In contrast, little change in the cytokine and chemokine arrays were observed in the RMS STING-/- TME following cryoablation, despite the host being fully capable of responding to STING activation (figure 7).”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
PremisecitationPrior reports have described an essential role for host STING pathway in cancer therapy.
“As prior reports have described an essential role for host STING pathway in cancer therapy,17 35 36 54”
Quote in the paperSubstantial claim0 of 1 sources checked- cites 17 35 36 54
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Classified as probably not a substantial claim.
Study design and conductown dataRMS 76-9STING-/- knockout efficiency was confirmed by western blot.
“gene knockout efficiency was confirmed by western blot.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenFlow cytometry analyses of TME immune composition were performed with freshly isolated single cell suspensions without freeze-thaw manipulations.
“All flow cytometry analyses of the TME immune composition were performed with freshly isolated single cell suspensions obtained on the same day of tumor harvesting without freeze-thaw manipulations.”
Quote in the paperNot a substantial claimMay combine two claims.
Study design and conductown dataTmem173 expression was ablated via CRISPR-Cas9 in RMS 76-9STING-/- cells, confirmed by western blot and qPCR.
“then ablated Tmem173 expression via CRISPR-Cas9 genome editing (RMS 76-9STING-/-), which was confirmed by both western blot (online supplemental figure S4A) and qPCR (online supplemental figure S4B).”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
PremisecitationdsDNA derived from tumor cells as a result of cytotoxic agents or stress can trigger STING pathway activation in nearby host APCs, resulting in the release of IFN-β, chemokines CXCL9/10, and enhanced cross-presentation of tumor antigens to CD8+ T cells.
“Previous studies have shown that dsDNA derived from tumor cells as a result of cytotoxic agents or stress can trigger STING pathway activation in nearby host APCs, resulting in the release of IFN-β, chemokines CXCL9/10, and enhanced cross-presentation of tumor antigens to CD8+ T cells.17 35 36 54–58”
Quote in the paperSubstantial claim0 of 1 sources checked- cites 17 35 36 54–58
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims. The quote only partly states this claim.
Interpretationown dataHost STING signaling activation and associated type I IFN production provide partial local tumor control following cryoablation but cannot fully account for the complete in vivo therapeutic effects observed in wild-type mice.
“our data indicate that the host STING pathway plays a partial role in regulating RMS 76-9 tumor growth, as the antitumor immune response of cryoablation was impaired but not completely abrogated in STING-/- mice (figure 3E).”
Quote in the paperSubstantial claim- Rests on an assumption: STING-/- mice lack functional host STING signaling.
May combine two claims.
Interpretationown dataCryoablation may activate antitumor immune responses by supporting DC maturation and recruitment of hematopoietic cells to the TME.
“These results suggest that cryoablation may activate antitumor immune responses by supporting DC maturation and recruitment of hematopoietic cells to the TME.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
Study design and conductreasoningOnly male mice were used to eliminate confounding issues related to H-Y dependent tumor rejection.
“To eliminate confounding issues related to H-Y dependent tumor rejection, only male mice were used in this study.”
Quote in the paperSubstantial claim- Rests on an assumption: RMS 76-9 originated from male mice, and female mice spontaneously reject inoculated tumor growth at a high frequency.
May combine two claims.
Interpretationown dataThe presence of an intact tumor cell-derived STING signaling is critical for in vivo tumor rejection not only in the setting of cryoablation but also in the setting of therapies involving direct STING agonist administration.
“These data suggest that the presence of an intact tumor cell-derived STING signaling is critical for in vivo tumor rejection not only in the setting of cryoablation (figures 4 and 5) but also is applicable in the setting of therapies involving direct STING agonist administration.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataTumor-intrinsic STING signaling drives both the local response to cryoablation and the generation of an effective systemic antitumor immunity.
“These results provide strong evidence that tumor-intrinsic STING signaling drives both the local response to cryoablation and the generation of an effective systemic antitumor immunity.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationTumor cells undergoing ICD actively export DNA fragments to initiate an innate immune response.
“Previous studies have reported that tumor cells undergoing ICD actively export DNA fragments to initiate an innate immune response.83 84”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites 83 84
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Classified as probably not a substantial claim. May combine two claims.
Interpretationown dataAn alternative source of STING signaling exists, or STING signaling does not completely account for the therapeutic efficacy of cryoablation.
“This finding suggests either an alternative source of STING signaling, or that STING signaling does not completely account for the therapeutic efficacy of cryoablation.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationSTING deficiency has a reported protective role in tumor cell death.
“the reported protective role of STING deficiency in tumor cell death.68 69”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites 68 69
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationThe presence of cytosolic dsDNA in APCs triggers host STING-mediated type I IFN activation and adaptive immunity.
“Consequently, the presence of cytosolic dsDNA in APCs triggers host STING-mediated type I IFN activation and adaptive immunity.17 32 35 36”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites 17 32 35 36
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Classified as probably not a substantial claim. May combine two claims.
PremisecitationTumors induced to undergo ICD can serve as 'in situ tumor vaccines' to activate DC and T cells, leading to the generation of an immunogenic hot TME and a robust systemic antitumor immune response.
“Tumors induced to undergo ICD can serve as ‘in situ tumor vaccines’ to activate DC and T cells, leading to the generation of an immunogenic hot TME and a robust systemic antitumor immune response.13 14”
Quote in the paperSubstantial claim0 of 1 sources checked- cites 13 14
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
Interpretationown dataThis suggests a correlation between the lack of tumor cell-intrinsic STING and tumor metastatic tendency or resistance to antitumor immunity.
“suggesting a correlation between the lack of tumor cell-intrinsic STING and tumor metastatic tendency or resistance to antitumor immunity.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationThe myeloid STING pathway is required for the antitumor immunity effects associated with multiple cancer therapeutics.
“reaffirmed prior studies showing the requirement of the myeloid STING pathway for the antitumor immunity effects associated with multiple cancer therapeutics,17 35 36”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites 17 35 36
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
Interpretationown dataThe loss of cryoablation efficacy in STING-/- tumors is not due to intrinsic survival advantage of the STING-/- tumor following cryoablation; rather, it is the lack of antitumor immunity in these tumors following the intervention that resulted in the lack of therapeutic efficacy.
“These data led us to believe that the loss of cryoablation efficacy in STING-/- tumors is not due to intrinsic survival advantage of the STING-/- tumor following cryoablation; rather, it is the lack of antitumor immunity in these tumors following the intervention that resulted in the lack of therapeutic efficacy.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationMice harboring the functionally deficient STINGS365A/365A point mutant are still capable of exhibiting STING-related IFN-independent activities.
“as mice harboring the functionally deficient STINGS365A/365A point mutant are still capable of exhibiting STING-related IFN-independent activities.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites 18 20 21
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationRecent evidence suggests the existence of IFN-independent activities of STING in hematopoietic-derived cells including T cells.
“recent evidence suggests the existence of IFN-independent activities of STING in hematopoietic-derived cells including T cells,18 20 21”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites 18 20 21
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
InterpretationreasoningPartial and sublethal cryoablation rather than complete cryoablation results in more robust response because leaving live, bulky tumor after the procedure to respond to cryoablated tumors may provide a more robust STING signaling in tumors with a functional STING signaling pathway.
“These data lend an explanation to the anecdotal clinical observation that partial and sublethal cryoablation rather than complete cryoablation results in more robust response since leaving live, bulky tumor after the procedure to respond to cryoablated tumors may provide a more robust STING signaling in tumors with a functional STING signaling pathway.”
Quote in the paperSubstantial claim
The paper relies on this without support.
The mechanism(s) driving cryoablation-induced local antitumor immunity and the associated abscopal effect is not well understood.
“The mechanism(s) driving cryoablation-induced local antitumor immunity and the associated abscopal effect is not well understood.”
The paper relies on this without support.
RMS 76-9 originated from male mice, and female mice spontaneously reject inoculated tumor growth at a high frequency.
“As rhabdomyosarcoma (RMS) cell line RMS 76-9 originated from male mice, female mice spontaneously reject inoculated tumor growth at a high frequency.”
The paper relies on this without support.
STING-/- mice lack functional host STING signaling.
“mice bearing RMS 76-9STING-/- tumors completely lack STING in both host and tumor.”
The authors state this as an assumption.
In STING-/- mice bearing RMS 76-9STINGwt tumors, the only source of intact STING signaling is the tumor cells.
“In this model, the only source of intact STING signaling pathway comes solely from RMS 76-9STINGwt, while mice bearing RMS 76-9STING-/- tumors completely lack STING in both host and tumor.”
The paper relies on this without support.
The molecular determinants driving clinical outcomes of tumor cryoablation are not well understood.
“The molecular determinants driving these clinical outcomes are not well understood.”
The paper relies on this without support.
Cryoablation has a distinct theoretical advantage over high-temperature or radio-ablation techniques in its ability to preserve intact tumor antigens and provide ICD-related DAMPs.
“A distinct theoretical advantage of cryoablation over high-temperature or radio-ablation techniques is its ability to preserve intact tumor antigens and provide ICD-related DAMPs.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Flow-cytometry tumor harvest is reported as both three and seven days after cryoablation
MinorThe tumor-isolation Methods assign flow-cytometry harvests to seven days after cryoablation, but the Figure 2 legend reports flow cytometry on tumors harvested three days afterward.
“Tumors were harvested either 3 days (qPCR and ELISA) or 7 days post cryoablation (flow cytometry)”
“Three days later, tumor tissue was analyzed by flow cytometry for the frequency of live CD11c+I-Ab+ and CD11c+CD80+ cells in the TME (n=4).”
T-cell depletion is dated differently in the Methods and Figure 1
MinorThe Methods say anti-CD4 or anti-CD8 was administered one day before cryoablation, on day 9 after inoculation. The Figure 1 legend instead says the antibodies were administered on day 10, the day of cryoablation.
“CD4+ or CD8+ T cell subsets were depleted in C57BL/6 tumor-bearing mice by administering 100 µg (in 100 µL of HBSS) of either anti-CD4 antibody (GK1.5) or anti-CD8 antibody (2.43) via intraperitoneal injection 1 day before cryoablation (9 days post inoculation) of tumor”
“About 100 µg of anti-CD4 (C) or anti-CD8 (D) mAb was then administrated on days 10, 13 and 16.”
Cites
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680 · see citing works
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119 · cited 1× · see citing works
“13 14 In support of this observation, studies have shown that variable duration and tissue applications of cryoablation resulted in differing necrotic and apoptotic cell death cores as well as varying immune activation landscapes in the treated area.”
Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA
Wu, J., Sun, L., Chen, X., Du, F., Shi, H., Chen, C., & Chen, Z. J. (2012) · Science · doi:10.1126/science.1229963 · Cited by 2,574 · cited 1× · see citing works
“34 35–37 Within tumor cells, the cGAS-STING pathway can be activated by cytosolic dsDNA originating from micro-nuclei secondary to the genomic instability of tumors, particularly those with mismatch repair deficiencies, 33 or after DNA-damaging therapies.”
Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing
Chen, Q., Sun, L., & Chen, Z. J. (2016) · Nature Immunology · doi:10.1038/ni.3558 · Cited by 2,333 · see citing works
The cGAS–STING pathway as a therapeutic target in inflammatory diseases
Decout, A., Katz, J. D., Venkatraman, S., & Ablasser, A. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00524-z · Cited by 2,309 · cited 1× · see citing works
“32 38–40 The cytosolic dsDNA activates cGAS in tumor cells, leading to cGAMP production 41 42 which is exported as a paracrine immu-notransmitter, subjected to degradation by extracellular hydrolase, ENPP1, 43 and imported into host myeloid cells through the SLC19A1 transporter, 41 44 thereby…”
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182 · see citing works
Thermal ablation of tumours: biological mechanisms and advances in therapy
Chu, K. F., & Dupuy, D. E. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3672 · Cited by 1,990 · see citing works
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917 · see citing works
cGAS surveillance of micronuclei links genome instability to innate immunity
Mackenzie, K. J., Carroll, P., Martin, C.-A., Murina, O., Fluteau, A., Simpson, D. J., Olova, N., Sutcliffe, H., Rainger, J. K., Leitch, A., et al. (2017) · Nature · doi:10.1038/nature23449 · Cited by 1,752 · see citing works
Chromosomal instability drives metastasis through a cytosolic DNA response
Bakhoum, S. F., Ngo, B., Laughney, A. M., Cavallo, J.-A., Murphy, C. J., Ly, P., Shah, P., Sriram, R. K., Watkins, T. B. K., Taunk, N. K., et al. (2018) · Nature · doi:10.1038/nature25432 · Cited by 1,638 · cited 1× · see citing works
“Detection of cytosolic dsDNA in the context of viral and bacterial infections, 26–29 aging and damaged cells, 30 or cancer, 31–33 is performed by the cytoplasmic DNA sensor, cGAS. cGAS catalyzes the formation of the second messenger cyclic dinucleotide (CDN), 2 ′ 3 ′ -cyclic- GMP-AMP (cGAMP).”
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560 · cited 1× · see citing works
“16 17 STING is an essential protein for the innate immune defense against a wide array of microbial pathogens.”
Mitotic progression following DNA damage enables pattern recognition within micronuclei
Harding, S. M., Benci, J. L., Irianto, J., Discher, D. E., Minn, A. J., & Greenberg, R. A. (2017) · Nature · doi:10.1038/nature23470 · Cited by 1,508 · see citing works
Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441 · see citing works
A bright monomeric green fluorescent protein derived from Branchiostoma lanceolatum
Shaner, N. C., Lambert, G. G., Chammas, A., Ni, Y., Cranfill, P. J. C., Baird, M. A., Sell, B., Allen, J. R., Day, R. N., Israelsson, M., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2413 · Cited by 1,260 · see citing works
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121 · see citing works
Pivotal Roles of cGAS-cGAMP Signaling in Antiviral Defense and Immune Adjuvant Effects
Li, X.-D., Wu, J., Gao, D., Wang, H., Sun, L., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1244040 · Cited by 1,097 · see citing works
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Gao, W., Wang, Y., Zhou, Y., Wang, X., & Yu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01046-3 · Cited by 1,069 · see citing works
cGAS is essential for cellular senescence
Yang, H., Wang, H., Ren, J., Chen, Q., & Chen, Z. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705499114 · Cited by 1,009 · cited 1× · see citing works
“Detection of cytosolic dsDNA in the context of viral and bacterial infections, 26–29 aging and damaged cells, 30 or cancer, 31–33 is performed by the cytoplasmic DNA sensor, cGAS. cGAS catalyzes the formation of the second messenger cyclic dinucleotide (CDN), 2 ′ 3 ′ -cyclic- GMP-AMP (cGAMP).”
Sen, T., Rodriguez, B. L., Chen, L., Corte, C. M. D., Morikawa, N., Fujimoto, J., Cristea, S., Nguyen, T., Diao, L., Li, L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1020 · Cited by 902 · see citing works
Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1218 · Cited by 743 · see citing works
Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer
Oh, D. Y., Kwek, S. S., Raju, S. S., Li, T., McCarthy, E., Chow, E., Aran, D., Ilano, A., Pai, C.-C. S., Rancan, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.017 · Cited by 734 · see citing works
Common Musculoskeletal Tumors of Childhood and Adolescence
Arndt, C. A. S., & Crist, W. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907293410507 · Cited by 657 · see citing works
Billingsley, K. G., Burt, M. E., Jara, E., Ginsberg, R. J., Woodruff, J. M., Leung, D. H. Y., & Brennan, M. F. (1999) · Annals of Surgery · doi:10.1097/00000658-199905000-00002 · Cited by 623 · see citing works
Marcus, A., Mao, A. J., Lensink-Vasan, M., Wang, L., Vance, R. E., & Raulet, D. H. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.016 · Cited by 609 · cited 3× · see citing works
“32 38–40 The cytosolic dsDNA activates cGAS in tumor cells, leading to cGAMP production 41 42 which is exported as a paracrine immu-notransmitter, subjected to degradation by extracellular hydrolase, ENPP1, 43 and imported into host myeloid cells through the SLC19A1 transporter, 41 44 thereby…”
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity
Demaria, O., Gassart, A. D., Coso, S., Gestermann, N., Domizio, J. D., Flatz, L., Gaide, O., Michielin, O. A., Hwu, P., Petrova, T. V., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512832112 · Cited by 574 · cited 2× · see citing works
“STING-related contributions to homeostasis and disease pathogenesis have been described in innate myeloid immune cells, 18 as well as T, 19–21 non-hematopoietic stromal 22 and endothelial 23–25 cells.”
Hydrolysis of 2′3′-cGAMP by ENPP1 and design of nonhydrolyzable analogs
Li, L., Yin, Q., Kuss, P., Maliga, Z., Millán, J. L., Wu, H., & Mitchison, T. J. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1661 · Cited by 539 · cited 2× · see citing works
“…leading to cGAMP production 41 42 which is exported as a paracrine immu-notransmitter, subjected to degradation by extracellular hydrolase, ENPP1, 43 and imported into host myeloid cells through the SLC19A1 transporter, 41 44 thereby triggering a type I IFN response and subsequent induction of…”
Signalling strength determines proapoptotic functions of STING
Gulen, M. F., Koch, U., Haag, S. M., Schuler, F., Apetoh, L., Villunger, A., Radtke, F., & Ablasser, A. (2017) · Nature Communications · doi:10.1038/s41467-017-00573-w · Cited by 505 · see citing works
The host STING pathway at the interface of cancer and immunity
Corrales, L., McWhirter, S. M., Dubensky, T. W., & Gajewski, T. F. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86892 · Cited by 487 · see citing works
TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity
Baccalà, R., Hoebe, K. H. N., Kono, D. H., Beutler, B., & Theofilopoulos, A. N. (2007) · Nature Medicine · doi:10.1038/nm1590 · Cited by 471 · see citing works
Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox
Oh, D. Y., & Fong, L. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.015 · Cited by 467 · see citing works
Cryoablation: Mechanism of Action and Devices
Erinjeri, J. P., & Clark, T. W. I. (2010) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2009.12.403 · Cited by 460 · see citing works
CD4 CTL, a cytotoxic subset of CD4(+) T cells, their differentiation and function
Takeuchi, A., & Saito, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00194 · Cited by 431 · see citing works
Granzymes in cancer and immunity
Cullen, S. P., Brunet, M., & Martin, S. J. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.206 · Cited by 391 · see citing works
The Pediatric Cancer Genome Project
Downing, J. R., Wilson, R. K., Zhang, J., Mardis, E. R., Pui, C., Ding, L., Ley, T. J., & Evans, W. E. (2012) · Nature Genetics · doi:10.1038/ng.2287 · Cited by 375 · see citing works
Wu, J., Dobbs, N., Yang, K., & Yan, N. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.009 · Cited by 373 · see citing works
Localized Extremity Soft Tissue Sarcoma: Improved Knowledge With Unchanged Survival Over Time
Weitz, J., Antonescu, C. R., & Brennan, M. F. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.026 · Cited by 365 · see citing works
Cutting Edge: Activation of STING in T Cells Induces Type I IFN Responses and Cell Death
Larkin, B., Ilyukha, V., Sorokin, M., Buzdin, A., Vannier, E., & Poltorak, A. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601999 · Cited by 361 · see citing works
STING cyclic dinucleotide sensing originated in bacteria
Morehouse, B. R., Govande, A. A., Millman, A., Keszei, A. F. A., Lowey, B., Ofir, G., Shao, S., Sorek, R., & Kranzusch, P. J. (2020) · Nature · doi:10.1038/s41586-020-2719-5 · Cited by 361 · cited 1× · see citing works
“Detection of cytosolic dsDNA in the context of viral and bacterial infections, 26–29 aging and damaged cells, 30 or cancer, 31–33 is performed by the cytoplasmic DNA sensor, cGAS. cGAS catalyzes the formation of the second messenger cyclic dinucleotide (CDN), 2 ′ 3 ′ -cyclic- GMP-AMP (cGAMP).”
SLC19A1 is an importer of the immunotransmitter cGAMP.
Ritchie, C., Cordova, A. F., Hess, G. T., Bassik, M. C., & Li, L. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.05.006 · Cited by 333 · see citing works
Wu, J., Chen, Y.-J., Dobbs, N., Sakai, T., Liou, J., Miner, J. J., & Yan, N. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20182192 · Cited by 323 · see citing works
STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade
Yang, H., Lee, W. S., Kong, S. J., Kim, C. G., Kim, J. H., Chang, S. K., Kim, S., Kim, G., Chon, H. J., & Kim, C. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125413 · Cited by 311 · cited 1× · see citing works
“STING-related contributions to homeostasis and disease pathogenesis have been described in innate myeloid immune cells, 18 as well as T, 19–21 non-hematopoietic stromal 22 and endothelial 23–25 cells.”
Li, W., Lu, L., Lu, J., Wang, X., Yang, C., Jin, J., Wu, L., Hong, X., Li, F., Cao, D., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay9013 · Cited by 305 · see citing works
Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes
Cerboni, S., Jeremiah, N., Gentili, M., Gehrmann, U., Conrad, C., Stolzenberg, M., Pïcard, C., Neven, B., Fischer, A., Amigorena, S., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20161674 · Cited by 292 · cited 1× · see citing works
“STING-related contributions to homeostasis and disease pathogenesis have been described in innate myeloid immune cells, 18 as well as T, 19–21 non-hematopoietic stromal 22 and endothelial 23–25 cells.”
Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity
Schadt, L., Sparano, C., Schweiger, N. A., Siliņa, K., Cecconi, V., Lucchiari, G., Yagita∥, H., Guggisberg, E., Saba, S., Naščáková, Z., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.065 · Cited by 290 · see citing works
DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity
Lu, C., Guan, J., Lu, S., Jin, Q., Rousseau, B., Lu, T., Stephens, D., Zhang, H., Zhu, J., Yang, M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.006 · Cited by 285 · cited 2× · see citing works
“Detection of cytosolic dsDNA in the context of viral and bacterial infections, 26–29 aging and damaged cells, 30 or cancer, 31–33 is performed by the cytoplasmic DNA sensor, cGAS. cGAS catalyzes the formation of the second messenger cyclic dinucleotide (CDN), 2 ′ 3 ′ -cyclic- GMP-AMP (cGAMP).”
Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti–CTLA-4 Therapy
Waitz, R., Solomon, S. B., Petre, E. N., Trumble, A. E., Fassò, M., Norton, L., & Allison, J. P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1782 · Cited by 282 · cited 1× · see citing works
“7 The release of tumor antigens from dying tumor cells can activate tumor-specific immune responses through antigen presentation by dendritic cells (DCs) to T cells, thereby allowing these adaptive cells to survey and destroy both ablated and non-ablated tumors at distant sites; this phenomenon is…”
Zhang, L., Mo, J., Swanson, K. V., Wen, H., Petrucelli, A., Gregory, S. M., Zhang, Z., Schneider, M., Jiang, Y., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.01.010 · Cited by 280 · see citing works
Non-canonical NF-κB Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy
Hou, Y., Liang, H. L., Rao, E., Zheng, W., Huang, X., Deng, L., Zhang, Y., Yu, X., Xu, M. M., Mauceri, H. J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.07.008 · Cited by 270 · see citing works
St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem
McLeod, C., Gout, A. M., Zhou, X., Thrasher, A., Rahbarinia, D., Brady, S. W., Macias, M., Birch, K., Finkelstein, D., Sunny, J., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1230 · Cited by 262 · see citing works
STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma
Hu, J. Y., Rivera, F. J. S., Wang, Z., Johnson, G. N., Ho, Y.-J., Ganesh, K., Umeda, S., Gan, S., Mujal, A. M., Delconte, R. B., et al. (2023) · Nature · doi:10.1038/s41586-023-05880-5 · Cited by 252 · see citing works
Linabery, A. M., & Ross, J. A. (2008) · Cancer · doi:10.1002/cncr.23866 · Cited by 246 · see citing works
Mechanisms of cryoablation: Clinical consequences on malignant tumors
Baust, J. G., Gage, A. A., Bjerklund Johansen, T. E., & Baust, J. M. (2014) · Cryobiology · doi:10.1016/j.cryobiol.2013.11.001 · Cited by 239 · cited 1× · see citing works
“15 To this end, mounting evidence suggests that activation of the cyclic GMP-AMP synthase–stimulator of interferon genes (cGAS-STING) innate immune sensing pathway in myeloid cells may be a critical link to ICD.”
Śledzińska, A., Vila de Mucha, M., Bergerhoff, K., Hotblack, A., Demane, D. F., Ghorani, E., Akarca, A. U., Marzolini, M. A. V., Solomon, I., Vargas, F. A., et al. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.007 · Cited by 228 · see citing works
STING enhances cell death through regulation of reactive oxygen species and DNA damage
Hayman, T. J., Baro, M., MacNeil, T., Phoomak, C., Aung, T. N., Cui, W., Leach, K., Iyer, R. P., Challa, S., Sandoval-Schaefer, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22572-8 · Cited by 210 · see citing works
Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis
Kaczanowska, S., Beury, D. W., Gopalan, V., Tycko, A. K., Qin, H., Clements, M. E., Drake, J. A., Nwanze, C., Murgai, M., Rae, Z., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.048 · Cited by 205 · see citing works
Falahat, R., Berglund, A., Putney, R. M., Perez-Villarroel, P., Aoyama, S., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013598118 · Cited by 190 · see citing works
Yang, Y., Wu, M., Cao, D., Yang, C., Jin, J., Wu, L., Hong, X., Li, W., Lu, L., Li, J., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf6290 · Cited by 187 · see citing works
Berger, G., Knelson, E. H., Jimenez-Macias, J. L., Nowicki, M. O., Han, S., Panagioti, E., Lizotte, P. H., Adu-Berchie, K., Stafford, A., Dimitrakakis, N., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111003119 · Cited by 179 · see citing works
Interferon-independent STING signaling promotes resistance to HSV-1 in vivo
Yamashiro, L. H., Wilson, S. C., Morrison, H. M., Karalis, V., Chung, J.-Y., Chen, K. J., Bateup, H. S., SZPARA, M. L., Lee, A. Y., Cox, J. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17156-x · Cited by 170 · see citing works
Crosstalk between cGAS–STING signaling and cell death
Murthy, A. M. V., Robinson, N., & Kumar, S. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-00624-8 · Cited by 170 · see citing works
Aaes, T. L., & Vandenabeele, P. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-00658-y · Cited by 167 · see citing works
Cryoablation and immunotherapy: an overview of evidence on its synergy
Aarts, B. M., Klompenhouwer, E. G., Rice, S. L., Imani, F., Baetens, T., Bex, A., Horenblas, S., Kok, M., Haanen, J. B. A. G., Beets-Tan, R. G. H., et al. (2019) · Insights into Imaging · doi:10.1186/s13244-019-0727-5 · Cited by 152 · see citing works
Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies
Kepp, O., Marabelle, A., Zitvogel, L., & Kroemer, G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0272-7 · Cited by 142 · see citing works
Heijink, A. M., Talens, F., Jae, L. T., van Gijn, S. E., Fehrmann, R. S. N., Brummelkamp, T. R., & van Vugt, M. A. T. M. (2019) · Nature Communications · doi:10.1038/s41467-018-07927-y · Cited by 140 · see citing works
Weigel, B. J., Rodeberg, D. A., Krieg, A. Μ., & Blazar, B. R. (2003) · PubMed · Cited by 133 · see citing works
Thermal Therapy, Part III: Ablation Techniques
Habash, R. W. Y., Bansal, R., Krewski, D. R., et al. (2007) · Critical Reviews in Biomedical Engineering · doi:10.1615/critrevbiomedeng.v35.i1-2.20 · Cited by 130 · see citing works
Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy
Berger, G., Marloye, M., & Lawler, S. E. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.02.007 · Cited by 116 · cited 1× · see citing works
“45 46 Our current study directly investigates the functional role of STING signaling in therapeutic response to cryoablation by determining whether there is a positive correlation between tumor ICD post-cryoablation and STING pathway activation.”
Low, J., Chandramohan, V., Bowie, M. L., Brown, M. C., Waitkus, M. S., Briley, A., Stevenson, K., Fuller, R., Reitman, Z. J., Muscat, A. M., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.009 · Cited by 101 · see citing works
Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors
Yakkala, C., Chiang, C. L.-L., Kandalaft, L., Denys, A., & Duran, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02283 · Cited by 88 · see citing works
Activation of Tumor-Cell STING Primes NK-Cell Therapy
Knelson, E. H., Ivanova, E. V., Tarannum, M., Campisi, M., Lizotte, P. H., Booker, M. A., Ozgenc, I., Noureddine, M., Meisenheimer, B., Chen, M., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0017 · Cited by 88 · see citing works
Ni, H., Zhang, H., Li, L., Huang, H., Guo, H., Zhang, L., Li, C., Xu, J.-X., Nie, C.-P., Li, K., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005151 · Cited by 85 · see citing works
Weld, K. J., & Landman, J. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05848.x · Cited by 84 · see citing works
Koscielniak, E., Rodary, C., Flamant, F., Carli, M., Treuner, J., Pinkerton, C. R., & Grotto, P. (1992) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950200305 · Cited by 83 · see citing works
Li, X., Deng, M., Petrucelli, A., Zhu, C., Mo, J., Zhang, L., Tam, J. W., Ariel, P., Zhao, B., Zhang, S., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.02.009 · Cited by 83 · see citing works
Cryoablation: physical and molecular basis with putative immunological consequences
Baust, J. G., Snyder, K. K., Santucci, K. L., Robilotto, A. T., Van Buskirk, R. G., & Baust, J. M. (2019) · International Journal of Hyperthermia · doi:10.1080/02656736.2019.1647355 · Cited by 76 · see citing works
Roy, I., McAllister, D. M., Gorse, E., Dixon, K. J., Piper, C., Zimmerman, N. P., Getschman, A. E., Tsai, S., Engle, D. D., Evans, D. B., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2645 · Cited by 74 · see citing works
Campbell, M. T., Matin, S. F., Tam, A. L., Sheth, R. A., Ahrar, K., Tidwell, R. S. S., Rao, P., Karam, J. A., Wood, C. G., Tannir, N. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26415-4 · Cited by 64 · cited 1× · see citing works
“8 9 In addition to shedding tumor antigens, cryoablated tumor tissues predominantly undergo immunogenic cell death (ICD), 10–12 which preserves intact tumor cell-derived antigens and releases damage-associated molecular patterns (DAMPs) such as double-stranded DNA (dsDNA), ATP, and heat shock…”
Vonderhaar, E. P., Barnekow, N. S., McAllister, D., McOlash, L., Eid, M. A., Riese, M. J., Tarakanova, V. L., Johnson, B. D., & Dwinell, M. B. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.01.018 · Cited by 61 · see citing works
cGAS-STING signaling encourages immune cell overcoming of fibroblast barricades in pancreatic cancer
Kabashima, A., Matsuo, Y., Ito, S., Akiyama, Y., Ishii, T., Shimada, S., Masamune, A., Tanabe, M., & Tanaka, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-14297-5 · Cited by 55 · see citing works
Luo, W.-W., Tong, Z., Cao, P., Wang, F.-B., Liu, Y., Zheng, Z.-Q., Wang, S.-Y., Li, S., & Wang, Y.-Y. (2022) · Nature Communications · doi:10.1038/s41467-022-32401-1 · Cited by 53 · see citing works
Jeong, S., Yang, M. J., Choi, S., Kim, J., & Koh, G. Y. (2021) · Nature Communications · doi:10.1038/s41467-021-24603-w · Cited by 42 · see citing works
Self-citationPercutaneous Image-Guided Cryoablation of Breast Cancer: A Systematic Review
Lanza, E., Palussière, J., Buy, X., et al. (2015) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2015.07.020 · Cited by 41 · see citing works
Cryosurgery/cryoablation in musculoskeletal neoplasms: history and state of the art
Rose, P. S., & Morris, J. M. (2015) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-015-9307-6 · Cited by 37 · see citing works
Murine rhabdomyosarcoma is immunogenic and responsive to T‐cell‐based immunotherapy
Meadors, J. L., Cui, Y., Chen, Q., Song, Y., Khan, J. I., Merlino, G. T., Tsokos, M., Orentas, R. J., & Mackall, C. L. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23048 · Cited by 37 · see citing works
Long-term outcome of breast cancer patients treated with radiofrequency ablation
Noguchi, M., Motoyoshi, A., Earashi, M., et al. (2012) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2012.08.006 · Cited by 35 · cited 1× · see citing works
“6 The ice ball created by cryoablation results in direct mechanical destruction of tissues and cells due to osmotic shock, ruptured cell membranes from ice crystal formation, and WHAT IS ALREADY KNOWN ON THIS TOPIC ⇒ Cryotherapy has been applied clinically, mostly for tumor debulking and pain…”
Reschke, R., & Olson, D. (2022) · Cancers · doi:10.3390/cancers14102458 · Cited by 28 · see citing works
Marloye, M., Lawler, S. E., & Berger, G. (2019) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2019-0013 · Cited by 25 · cited 1× · see citing works
“45 46 Our current study directly investigates the functional role of STING signaling in therapeutic response to cryoablation by determining whether there is a positive correlation between tumor ICD post-cryoablation and STING pathway activation.”
Veenstra, J. J., Gibson, H. M., Littrup, P. J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0501 · Cited by 22 · see citing works
Kim, J. C., Liu, X., Fitzgerald, K., Eng, J. S., Orf, J., O’Brien, S. A., Belmontes, B., Casbon, A.-J., Novitskiy, S. V., Tarbell, K. V., et al. (2023) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-022-03327-w · Cited by 22 · see citing works
Abscopal Effect following Cryoablation of Breast Cancer
Kumar, A., Patterson, S. G., & Plaza, M. J. (2019) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2018.12.004 · Cited by 21 · see citing works
Rate of Freeze Impacts the Survival and Immune Responses Post Cryoablation of Melanoma
Yakkala, C., Dagher, J., Sempoux, C. L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.695150 · Cited by 19 · cited 2× · see citing works
“8 9 In addition to shedding tumor antigens, cryoablated tumor tissues predominantly undergo immunogenic cell death (ICD), 10–12 which preserves intact tumor cell-derived antigens and releases damage-associated molecular patterns (DAMPs) such as double-stranded DNA (dsDNA), ATP, and heat shock…”
Wu, Y., Tang, C.-H. A., Mealer, C., Bastian, D. A., Sofi, M. H., Tian, L., Schutt, S. D., Choi, H.-J., Ticer, T. D., Zhang, M., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00611-6 · Cited by 11 · see citing works
Jenson, J. M., & Chen, Z. J. (2020) · Nature · doi:10.1038/d41586-020-02712-8 · Cited by 7 · see citing works
Rosenberg, M. A., & Williams, J. H. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-p142 · Cited by 5 · see citing works
Arwert, E. N., Milford, E. L., Rullan, A., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0544-6 · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Piezo1 facilitates optimal T cell activation during tumor challenge
Abiff, M., Alshebremi, M., Bonner, M., Myers, J., Kim, B., Tomchuck, S. L., Santin, A., Kingsley, D., Choi, S. H., & Huang, A. Y.-C. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2281179 · Cited by 24 · see citing works
“…cryoablated versus non-cryoablated WT mice; however, neither marker was appreciably different in cryoablated versus non-cryoablated P1KO mice (Figure 2f,g). tDLN CD4 + T cells in tumor-bearing P1KO mice exhibited higher PD-1 expression on day 14–16, which then normalized by day 22 (Figure S5a,b).”
BackgroundSelf-citationGu, S., Luo, Q., Zhang, Y., Qian, L. M., Chen, K., Liang, F., Hu, Y., Zhou, R., Wang, Y., Liu, J., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01058-2 · Cited by 19 · see citing works
Lin, S., Liu, D., Liang, T., Zhuang, Y., Wang, X., Ma, S., Li, Q., & Hu, K. (2025) · BMC Medicine · doi:10.1186/s12916-025-03926-1 · Cited by 13 · see citing works
“The temperature of each cycle was reduced to − 120 °C for 10 s, followed by rewarming to 10 °C [22–24].”
Piezo1 deletion enhances cross-priming of CD8+ T cells by tumor-infiltrating CD11b+ dendritic cells
Bonner, M., Askew, D., Kumar, V. S., Tomchuck, S. L., Eid, S. K., Abiff, M., Myers, J., Nguyen, P. Q. T., Garyu, J., Miller, T. E., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011815 · Cited by 13 · see citing works
“11 12 Last, we investigated immune cell populations in the spleen, an organ rich in cDC1s capable of cross-presenting antigens to both CD4+ and CD8+ T cells, and the primary site of accumulation of myeloid-derived suppresor cells (MDSCs) of granulocytic (G-MDSC) and monocytic (M-MDSC) origins.”
Self-citationYu, D. N., Yang, Z., Qi, M., & Zhong, H. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189393 · Cited by 6 · see citing works
Nanostrategies synergize with locoregional interventional therapies for boosting antitumor immunity
Luo, T., Ma, K., Zhang, Y., Xue, Q., Yu, J., Liang, X., & Liang, P. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.05.016 · Cited by 5 · see citing works
“In mouse cancer models, the STING-dependent type I IFN signaling pathway was mechanistically responsible for enhanced systemic immune response [132,133].”
STING activation reshapes the tumor microenvironment leading to tumor regression in osteosarcomaPreprint
Young, E. P., Johnson, C. A., Lee, A. G., Morris, D., Tsui, J. L., Breese, M. R., Cámara, J. A., Schott, C. R., Abram, C. L., Leung, S. G., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.24.684275 · Cited by 2 · see citing works
Multimodal thermal therapy for solid tumor: a new interventional immunomodulatory therapy
Lou, Y. L., Liu, P., & Xu, L. X. (2026) · Med-X · doi:10.1007/s44258-025-00068-0 · Cited by 1 · see citing works
Amine oxide lipid nanoparticles for delivery of cyclic dinucleotides
Chen, Y., Yang, Y., Xiao, F., et al. (2026) · National Science Review · doi:10.1093/nsr/nwag340 · Cited by 1 · see citing works
“While tumor cells inter-nalize a proportion of STING-activating LNPs, emerging evidence highlights the pivotal role of tumor cell-intrinsic STING pathway in suppressing metastases, elevating IFN-I levels, and recruiting T cells for immune surveillance [35 ,42 –45 ].”
Wang, X., Zhang, M., Liu, D., Lin, S., Zhang, Y., & Li, Q. (2025) · Scientific Reports · doi:10.1038/s41598-025-14655-z
“A skin incision was made along the longitudinal axis of the tumor to fully expose the tumor mass. CRYO-SL argon-helium knife cryotherapy system (Tianjin, China) was used for ablation concerning the modified double-cycle cryotherapy protocol 10,14 .”
Development of 68Ga-labeled macrocyclic peptide for targeting stimulator of interferon genes
Zhang, J., Meng, L., Li, H., Xia, D., Wang, X., Zhuang, R., Liu, H., Li, Y., Zhang, X., Fang, J., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.03.010
An Overview of STING as an Anticancer Target: Structure, Function, and Inhibitors
Chang, Y., Dan, E., Zhang, H., & Cao, S. (2026) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2026.146010
Wang, H., Wang, C., Shi, H., et al. (2026) · EngMedicine · doi:10.1016/j.engmed.2026.100140
Hama, M. A., Madhat, M. A., Awlqadr, F. H., Mahmood, A. H. A., Abdalla, R. A., Ali, R. K., Kareem, S. H. T., Hama, N. E., Hamalaw, S. R., & AL-Farga, A. M. (2026) · Medical Oncology · doi:10.1007/s12032-026-03396-2
- Authors
- Alshebremi, M., Tomchuck, S. L., Myers, J. T., Kingsley, D. T., Eid, S., Abiff, M., Bonner, M., Saab, S. T., Choi, S. H., & Huang, A. Y.-C.
- Affiliations
- Qassim University (SA)
- Case Western Reserve University (US)
- University Hospitals Cleveland Medical Center (US)
- Rainbow Babies & Children's Hospital (US)
- Corresponding author
- Huang, Alex Yee-Chen
- ORCID
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2023-08
- Volume
- 11
- Issue
- 8
- Pages
- e006608
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC10414127
- OpenAlex
- W4385666785
- Semantic Scholar
- e8c96921ac006d5a5a8fa384f3f282bbbefe6fb0
- Cited by
- 14
- References
- 98
- Citations by year
- 2026: 6 · 2025: 7 · 2023: 1
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Alan & Karen Krause Family Foundation (N/A)
- Sarcoma Foundation of America (836338)
- Pediatric Cancer Research Foundation (580546)
- Center for Pediatric Immunotherapy at the Angie Fowler AYA Cancer Institute / UH Rainbow Babies & Children’s Hospital (N/A)
- The Cleveland Foundation (N/A)
- St. Baldrick's Foundation (712502, 605146, 550928)
- ORIP (S10OD024981)
- Theresia G. & Stuart F. Kline Family Foundation (N/A)
- Harrington Discovery Institute (N/A)
- NIH/NCI (F31CA254259, T32CA059366)
- NIH/NIGMS (T32GM007250)
- The Char & Chuck Fowler Family Foundation
- The I'm Not Done Yet Foundation
- Children’s Cancer Research Fund (897798)
- Alex's Lemonade Stand Foundation for Childhood Cancer (N/A)
- Case Comprehensive Cancer Center AYA Oncology Pilot Grant (N/A)
- Case Comprehensive Cancer Center - VeloSano Bike to Cure Pilot Award
- The Risman Family Philanthropic Funds
- MIB Agents
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- STING signaling, cryoablation, abscopal effect, antitumor immunity, tumor microenvironment, lung metastasis, tumor-infiltrating immune cells, treatment response biomarkers
- MeSH terms
- Animals, Cryosurgery, Lung Neoplasms, Mice, Inbred C57BL, Cytokines, Mice, Adaptive Immunity, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-19.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-19.
Cited sources are checked by gpt-6-sol.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review